UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES AND EXCHANGE ACT OF 1934
APRIL 21, 2005
Date of Report (date of Earliest Event Reported)
ISOLAGEN, INC.
(Exact Name of Registrant as Specified in its Charter)
|
DELAWARE |
|
001-31564 |
|
87-0458888 |
|
(State or
Other Jurisdiction of |
|
(Commission File No.) |
|
(I.R.S. Employer Identification No.) |
102 PICKERING WAY, EXTON, PENNSYLVANIA 19341
(Address of principal executive offices and zip code)
(484) 875-3099
(Registrant’s telephone number, including area code)
NOT APPLICABLE
(Former name or former address, if changed from last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-14(c)).
ITEM 5.02 DEPARTURE OF DIRECTORS OR PRINCIPAL OFFICERS; ELECTION OF DIRECTORS; APPOINTMENT OF PRINCIPAL OFFICERS.
(a) Not applicable.
(b) On April 21, 2005, Mr. Robert Bitterman resigned as chief executive officer, president, and director of Isolagen, Inc. (“Isolagen”). Mr. Bitterman’s resignation was not due to any disagreement with Isolagen on any matter relating to Isolagen’s operations, policies or practices. Mr. Bitterman has not furnished Isolagen with any written correspondence concerning the circumstances surrounding his resignation. Mr. Bitterman was provided with a copy of this report and has indicated his agreement with the statements made by Isolagen herein.
(c) Not applicable.
(d) Not applicable.
[THE SIGNATURE PAGE FOLLOWS]
2
SIGNATURE
Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
ISOLAGEN, INC. |
||
|
|
|
|
|
|
|
|
|
|
|
|
|
Date: April 27, 2005 |
|
By: |
/s/ Martin E. Schmieg |
|
|
|
|
|
Martin E. Schmieg, |
|
|
|
|
|
CFO & Sr. Vice President |
|
3